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BAFF levels are increased in patients with CTCL
Ohmatsu et al. investigated the role of B-cell-activating fac-
tor belonging to the tumour necrosis factor family (BAFF) in 
cutaneous T-cell lymphoma (CTCL). Lesional skin of CTCL 
contained higher levels of BAFF mRNA than normal skin 
and the expression levels correlated with disease activity. 
BAFF mRNA expression levels were elevated in fibroblasts 
from CTCL skin. Tumour cells in the lesional skin of CTCL 
expressed BAFF and its receptors, while fibroblasts expressed 
only BAFF. Serum BAFF levels of patients with CTCL were sig-
nificantly higher than those of healthy controls and correlated 
with types of skin lesions and clinical stages. They also cor-
related significantly with serum soluble interleukin-2 receptor 
and lactate dehydrogenase levels. The results suggest that 
BAFF may have important roles in the development of CTCL 
in both an autocrine and a paracrine manner. Br J Dermatol 
2012; 167: 359–67
Infliximab for psoriasis: 9 years’ experience of 
infusion reactions
Wee et al. report a retrospective review of infliximab infusions 
in patients with psoriasis from their centre. Fifty-nine consecu-
tive patients received a total of 858 infliximab infusions over a 
9-year period. The incidence of infusion reactions was 1.5%, 
affecting 17% of patients. Mild, moderate and severe acute 
reactions occurred in 0.6%, 0.3% and 0.3% of infliximab 
infusions, respectively. The prevalence of infusion reactions in 
patients receiving infliximab alone was 27% compared with 
4% in those receiving concomitant methotrexate. One infu-
sion reaction occurred in the postinfusion period (10 min after 
infusion completion). The very low incidence and occurrence 
of almost all reactions during the first hour of the infusion 
provides support for safely shortening the monitoring period 
to no longer than 1 h, especially in uncomplicated patients 
established on treatment. Br J Dermatol 2012; 167: 411–16
SCLE and its association with drugs
Grönhagen et al. performed a population-based matched 
case–control study in which 234 cases of subacute cutaneous 
lupus erythematosus (SCLE) from 2006 to 2009 were derived 
from the Swedish National Patient Register. During the 6 
months preceding SCLE diagnosis, 71% of the patients had 
at least one filled prescription for the suspected drugs. More 
than one third of the SCLE cases could be attributed to drug 
exposure. The most increased odds ratios were found for ter-
binafine, tumour necrosis factor-α inhibitors, antiepileptics 
and proton pump inhibitors. Drug-induced SCLE is revers-
ible once the drug is discontinued, indicating the importance 
of screening patients with SCLE for potentially triggering 
drugs. A causal relationship cannot be established from this 
study and the underlying pathogenesis remains unclear. Br J 
Dermatol 2012; 167: 296–305
RCM for monitoring UVB phototherapy  
in psoriasis
This study is the first to establish the use of in vivo reflectance 
confocal microscopy (RCM) as an effective tool for noninva-
sive monitoring of ultraviolet (UV) B phototherapy in patients 
with psoriasis. RCM was performed before the first irradiation 
with UVB phototherapy, after nine irradiations, at clearance 
and 12 weeks after clearance. In four patients, 4-mm punch 
biopsies were obtained and stained with haematoxylin and 
eosin. Additionally, immunohistochemical staining was per-
formed with monoclonal antibodies specific for CD31, CD3, 
filaggrin, keratin 16, Ki-67 and CD1a for correlation to RCM 
images. Normalization of RCM and (immuno)histological 
features corresponded highly to clinical improvement of pso-
riasis. Br J Dermatol 2012; 167: 396–403
